Cardiol Therapeutics (CRDL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CRDL Cardiol Therapeutics

Watchlist

1.7900
-0.0300-1.65%

Close Nov 18 16:00 ET

146.07MMarket Cap-4649P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study
Benzinga11:38 ET
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
newsfile11:37 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Cardiol Therapeutics Faces Rising Losses and Falling Assets
TipRanksNov 14 17:18 ET
Cardiol Therapeutics Added to PRISM Emerging Biotech Index
TipRanksNov 13 08:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
BenzingaOct 24 07:32 ET

Comments

Jaguar8

19 hours ago

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics (NASDAQ: CRDL) reported positive Phase II MAvERIC-Pilot clinical results for CardiolRx™ in treating recurrent pericarditis. The study showed marked improvements in pericarditis pain and inflammation maintained throughout the 26-week study. The trial enrolled 27 participants across eig...

Jaguar8

Oct 10 08:09

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Jaguar8

Sep 24 06:52

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include...

Trytosaveabit

Sep 10 06:43

Update! Note the date as well!

$Cardiol Therapeutics (CRDL.US)$ Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis With Results to Be Presented at the American Heart Association Scientific Sessions 2024
newsfile·
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024

Jaguar8

Jun 13 06:59

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CRDL Cardiol Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target